Antibiotic-Resistant Infections Rise 17% in England

This site is intended for healthcare professionals

Antibiotic-Resistant Bloodstream Infections Rise 17% in England

Key Summary:

  • England recorded 21,129 antibiotic-resistant bloodstream infection episodes in 2025.
  • Escherichia coli and Klebsiella pneumoniae accounted for most of the increase in resistant infections.
  • Older adults, infants, and socioeconomically deprived populations faced a disproportionate burden of AMR.

Antibiotic-resistant bloodstream infections in England have increased by nearly 17% since 2019, according to new surveillance data released by the UK Health Security Agency (UKHSA) ahead of World Antimicrobial Resistance Awareness Week 2026. The findings highlight the growing burden of antimicrobial resistance (AMR), with more than 400 episodes of resistant bloodstream infections recorded every week.

The latest English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) report, published on 12th November 2026, revealed that the number of bloodstream infection episodes involving bacteria resistant to at least one specified antibiotic increased from 18,086 in 2019 to 21,129 in 2025, representing a 16.8% rise.

Although the increase continued between 2024 and 2025, the rate of growth slowed to 3.2%, compared with 9.3% in the preceding year. Nevertheless, approximately 22% of bloodstream infection episodes caused by the pathogens included in the AMR burden assessment were resistant to one or more specified antibiotics, highlighting the persistent challenge of drug-resistant infections.

Gram-Negative Bacteria Drive Rising Resistance

Gram-negative bacteria remained the leading contributors to antibiotic-resistant bloodstream infections, with Enterobacterales accounting for 85.5% of resistant episodes in 2025.

Escherichia coli continued to represent the greatest burden, contributing approximately 70% of resistant infections, while the proportion attributed to Klebsiella pneumoniae increased from 11.1% in 2019 to 13.4% in 2025. Together, these two pathogens accounted for 88.4% of the increase in resistant bloodstream infections over the surveillance period.

Resistance to several commonly used antibiotics also increased. Notably, resistance to piperacillin-tazobactam in K. pneumoniae reached 22.8% in 2025, almost double the 11.9% reported for E. coli. Meanwhile, co-amoxiclav resistance remained particularly high in E. coli, affecting 43.1% of isolates.

The findings raise concerns about the effectiveness of established treatment options for serious bacterial infections and reinforce the importance of antimicrobial stewardship, appropriate prescribing, and continued resistance surveillance.

Health Inequalities Shape AMR Burden

The report also identified substantial inequalities in the distribution of antibiotic-resistant infections across England.

Adults aged 75 years and older accounted for approximately half of resistant bloodstream infection episodes and experienced the highest rates of resistance. Infants younger than 1 year also faced a disproportionately high burden, with rates second only to those observed in the oldest age group.

Marked differences were observed across ethnic groups. Among bloodstream infection episodes involving the pathogens assessed, resistance was identified in 42.4% of episodes in Asian or Asian British patients and 32.8% in Black, African, Caribbean, or Black British patients, compared with 20.7% in White patients.

Socioeconomic deprivation was another significant factor. Rates of resistant bloodstream infections were consistently higher in the most deprived populations, with the gap between the most and least deprived groups widening from 29% in 2019 to 44.2% in 2025.

These findings highlight the importance of targeted public health interventions that address inequalities in infection prevention, diagnosis, and treatment.

Emerging Resistance Threatens Treatment Options

Beyond Gram-negative bacteria, the report highlighted increasing resistance among other clinically important pathogens.

Methicillin-resistant Staphylococcus aureus (MRSA) accounted for 7.3% of S. aureus bloodstream infection episodes in 2025. Tetracycline resistance among MRSA isolates more than doubled between 2019 and 2025, increasing from 13.3% to 31.3%.

Emerging fungal threats also remain a concern. In 2025, 213 patients were newly identified with Candidozyma auris, formerly known as Candida auris, including 38 patients with invasive infections. Approximately 60% of detections were associated with declared healthcare outbreaks, predominantly in London and South-East England.

Urgent Action Needed to Address AMR

The findings also raise questions about progress towards the UK’s 2024–2029 National Action Plan on AMR, which aims to prevent increases in specified drug-resistant infections and reduce the burden of serious bacterial infections.

According to the report, specified drug-resistant infections in England remained 25.7% above the 2019–2020 financial year baseline, while Gram-negative bloodstream infections had increased by 8%.

As World Antimicrobial Resistance Awareness Week draws attention to the global threat of drug-resistant infections, these findings reinforce the need for strengthened infection prevention, improved diagnostic capabilities, responsible antimicrobial prescribing, and targeted interventions for populations at greatest risk.

Although the latest figures suggest that the growth in resistant bloodstream infections may be slowing, the continuing rise in absolute numbers demonstrates that AMR remains a substantial and evolving public health challenge.

Reference

UK Health Security Agency. ESPAUR report 2025 to 2026: Chapter 2. Antimicrobial resistance (AMR). Published 12th November 2026. Available at: https://www.gov.uk/government/publications/english-surveillance-programme-for-antimicrobial-utilisation-and-resistance-espaur/espaur-report-2025-to-2026-chapter-2-antimicrobial-resistance-amr

Adobe Stock

Author:

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.